Neuroverse is committed to the development of a suite of mobile applications, the BrainVitals® apps, paired with the BrainStation® device, and leveraging Neuroverse advanced analytics, to enable specific solutions for neurological and psychiatric pathologies.

Neuroverse is developing a mobile solution for migraine patients to be able to self-track at home and predict upcoming migraine attacks before onset of symptoms.

The first clinical study yielded very encouraging results, presented at the American Headache Society and European Headache Federation meetings, with great feedback from world migraine experts.

Neuroverse has currently various partnerships exploring future solutions in additional neurological and psychiatric pathologies.

Neuroverse has an established partnership for the characterization of the brain processes and determination of relevant biomarkers associated with anxiety states, as well as therapeutic intervention effects. This collaborative work is already yielding encouraging preliminary results, suggesting correlations of neural modulations in different frequency bands with changes in the anxiety state of a clinical population.

Neuroverse completed a collaborative study in the determination of reliable biomarkers for schizophrenia.

Results show that the BrainStation® system successfully identified reductions of amplitude in three brain markers associated with cognitive deficits observed in schizophrenia, suggesting this system's potential to enable large scale assessment not limited to medical centers.